Article

Surgical Treatment of Benign Prostatic Hyperplasia (sponsored)

On January 10, 2015 Urology Times convened an expert panel to examine the criteria that constitute a gold standard for the treatment of male lower urinary tract symptoms (LUTS), or benign prostatic hyperplasia (BPH).

 

Surgical Treatment of Benign Prostatic Hyperplasia

What Defines a Gold Standard?



On January 10, 2015 Urology Times convened an expert panel to examine the criteria that constitute a gold standard for the treatment of male lower urinary tract symptoms (LUTS), or benign prostatic hyperplasia (BPH).

 

 

Related Videos
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Landon Trost, MD, answers a question during a Zoom video interview
Anna Myers, CNP, answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
1 expert in this video
Perry Xu, MD, answers a question during a Zoom video interview
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Related Content
Bel-sar shows promising safety, efficacy in NMIBC
March 26th 2025

Bel-sar shows promising safety, efficacy in NMIBC

Hannah Clarke
In patients with intermediate-risk disease, 4 of 5 patients demonstrated a complete response.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA approves gepotidacin for uncomplicated UTI
March 25th 2025

FDA approves gepotidacin for uncomplicated UTI

Hannah Clarke
The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
WATER III: Aquablation achieves comparable outcomes to laser enucleation for BPH
March 24th 2025

WATER III: Aquablation achieves comparable outcomes to laser enucleation for BPH

Hannah Clarke
The mean change in IPSS from baseline to 3 months was 12.9 in the Aquablation arm vs 13.1 in the LEP arm.
Additional NIAGARA data reinforce benefit of perioperative durvalumab in MIBC
March 24th 2025

Additional NIAGARA data reinforce benefit of perioperative durvalumab in MIBC

Hannah Clarke
“The addition of the durvalumab did not make treatment more morbid than chemotherapy alone, and it didn't change or increase the surgical complications you saw in the ward," says James W.F. Catto, MBChB, PhD, FRCS.
© 2025 MJH Life Sciences

All rights reserved.